Chintu Patel is the Co-Chief Executive Officer of Amneal Pharmaceuticals, Inc., a company he co-founded to develop and deliver innovative pharmaceutical products. Born in 1974 and educated with a Bachelor's degree in pharmacy from Rutgers College of Pharmacy, Chintu has...

Chintu Patel is the Co-Chief Executive Officer of Amneal Pharmaceuticals, Inc., a company he co-founded to develop and deliver innovative pharmaceutical products. Born in 1974 and educated with a Bachelor's degree in pharmacy from Rutgers College of Pharmacy, Chintu has a strong background in pharma. Under his leadership, Amneal has focused on creating medications that address critical health needs. Interestingly, Chintu and his brother Chirag both opted for a salary of just $1 when they became co-CEOs in 2019, demonstrating their commitment to aligning their interests with the company's shareholders. Chintu has also played a key role in potential mergers and acquisitions within the healthcare sector, including several startups in drug delivery technologies. He is known for his strategic vision, having transitioned Amneal during a time of market shifts while maintaining a commitment to corporate governance and ethical practices.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Amneal Pharmaceuticals, Inc. CEOs

A

Chintu Patel

Founder and Ex-CEO of Amneal Pharmaceuticals, Inc.

Education

Bachelor's degree in pharmacy from Rutgers College of Pharmacy.

Sector of Economy

Healthcare

Born

January 1, 1974 - 51 years ago

CEO of Amneal Pharmaceuticals, Inc. for

2 years 7 months (Aug 2019 - Mar 2022)

Previous Experience

Co-Founder of Amneal Pharmaceuticals, LLC and served as Co-Chairman and Co-Chief Executive Officer from 2002 to 2017.

Rivals

Competitors/colleagues of Chintu Patel

Holdings

See how much did Chintu Patel make over time.

Chintu Patel has significant holdings in Amneal Pharmaceuticals, Inc., where he closely monitors his investments, reflecting his commitment to the company's success. Notably, his wealth is largely tied to Amneal's performance, where he has substantial shares in the Class A...

Chintu Patel has significant holdings in Amneal Pharmaceuticals, Inc., where he closely monitors his investments, reflecting his commitment to the company's success. Notably, his wealth is largely tied to Amneal's performance, where he has substantial shares in the Class A common stock. Since stepping into the CEO role in 2019, maintaining a focus on shareholder value, Chintu’s wealth peaked alongside Amneal’s growth periods. Despite fluctuations in the pharmaceutical market, his stake has remained a key factor in his financial profile, serving as an incentive to drive the company's success. Currently, Chintu holds about 565,000 shares of Class A stock and controls a significant portion of Class B shares, emphasizing his deep commitment to the firm he helped build.

Insider Trading

See recent insider trades of Chintu Patel.

AMRX

$628.50K

AMRX at $4.19/share

Dec 15, 2021

Purchase

AMRX

$309.00K

AMRX at $3.09/share

Mar 10, 2020

Purchase

AMRX

$976.67K

AMRX at $3.91/share

Mar 2, 2020

Purchase

Compensation History

See how much did Chintu Patel make over time.

In 2022, Chintu Patel's total compensation was reported at $950,000, consisting of a $500,000 base salary and performance-driven components like a $100,000 bonus based on company targets. He received $300,000 in vested stock from a long-term incentive plan aimed at encouraging performance over multiple years. However, it’s important to note that Patel and his brother Chirag elected to take a salary of just $1 when they became co-CEOs, underlining their focus on shareholder alignment rather than drawing high salaries. This compensation structure is part of a carefully crafted approach that links their earnings directly to the performance of Amneal, promoting a long-term growth mindset.

Year

2022

Total Compensation

$950.00K

Salary

$500.00K

Board Justification

The compensation philosophy is designed to align CEO compensation with company performance, market competitiveness, and retention strategies.

Bonus

$100.00K

Board Justification

The bonus is based on the company's performance metrics including revenue growth and EBITDA targets for the fiscal year 2022.

Other

$50.00K

Board Justification

Other compensation includes health benefits, retirement contributions, and perquisites.

Restricted Stock

$300.00K(20K RSU)

Board Justification

The stock that vested in 2022 was part of a long-term incentive plan based on performance metrics over a three-year period.

Performance Metrics

Performance metrics include revenue growth, EBITDA targets, and total shareholder return.

Other Amneal Pharmaceuticals, Inc. CEOs

Here are other CEOs of Amneal Pharmaceuticals, Inc.

Robert Stewart

Ex-CEO of Amneal Pharmaceuticals, Inc.

May 2018 - August 2019

Gustavo J. Pesquin

CEO of Amneal Pharmaceuticals, Inc.

September 2022 - Present